Vision Capital Management Inc. Buys 1,502 Shares of IQVIA Holdings Inc. $IQV

Key Points

• Vision Capital Management Inc. increased its stake in IQVIA Holdings Inc. by 4.5%, acquiring an additional 1,502 shares, bringing its total holdings to 35,146 shares valued at approximately $5.54 million.
• The stock of IQVIA has fluctuated, with a twelve-month range between $134.65 and $237.34, and a current price of $176.72, reflecting a 2.5% decline recently.
• Analysts are optimistic, with a consensus rating of "Moderate Buy" and an average price target of $229.64, supported by recent upgrades from multiple firms.

Vision Capital Management Inc. boosted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 4.5% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 35,146 shares of the medical research company's stock after acquiring an additional 1,502 shares during the quarter. Vision Capital Management Inc.'s holdings in IQVIA were worth $5,539,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of IQV. Pacer Advisors Inc. grew its stake in shares of IQVIA by 5,036.1% during the first quarter. Pacer Advisors Inc. now owns 871,704 shares of the medical research company's stock valued at $153,681,000 after buying an additional 854,732 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of IQVIA by 45.7% during the first quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company's stock valued at $448,686,000 after buying an additional 798,534 shares during the last quarter. Hawk Ridge Capital Management LP bought a new position in shares of IQVIA during the first quarter valued at approximately $77,096,000. Nuveen LLC bought a new position in shares of IQVIA during the first quarter valued at approximately $76,328,000. Finally, GAMMA Investing LLC grew its stake in shares of IQVIA by 27,448.4% during the first quarter. GAMMA Investing LLC now owns 387,331 shares of the medical research company's stock valued at $68,286,000 after buying an additional 385,925 shares during the last quarter. Institutional investors own 89.62% of the company's stock.

Insider Buying and Selling at IQVIA

In other news, insider Keriann Cherofsky sold 549 shares of the stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the sale, the insider owned 2,910 shares in the company, valued at approximately $557,352.30. This represents a 15.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Eric Sherbet sold 5,800 shares of the stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the sale, the insider owned 27,178 shares of the company's stock, valued at approximately $5,165,178.90. This represents a 17.59% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company's stock.

IQVIA Stock Down 2.5%

IQVIA stock opened at $176.72 on Friday. The business has a fifty day moving average of $186.64 and a two-hundred day moving average of $167.31. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45. The firm has a market cap of $30.04 billion, a P/E ratio of 25.57, a P/E/G ratio of 1.99 and a beta of 1.32. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $237.34.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, beating the consensus estimate of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The firm had revenue of $4.02 billion during the quarter, compared to analyst estimates of $3.96 billion. During the same quarter in the prior year, the business posted $2.64 EPS. The business's revenue for the quarter was up 5.3% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Robert W. Baird upped their target price on IQVIA from $159.00 to $196.00 and gave the company a "neutral" rating in a research note on Wednesday, July 23rd. UBS Group increased their price objective on IQVIA from $185.00 to $225.00 and gave the stock a "buy" rating in a research note on Wednesday, July 23rd. Jefferies Financial Group raised IQVIA from a "hold" rating to a "buy" rating and increased their price objective for the stock from $195.00 to $225.00 in a research note on Tuesday, September 9th. Cowen reissued a "buy" rating on shares of IQVIA in a research note on Wednesday, July 23rd. Finally, Redburn Partners set a $214.00 price objective on IQVIA in a research note on Wednesday, September 3rd. Eighteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $229.64.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.